Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) To Present At Healthcare Conference

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare…

Batu Biologics Recruits Inventor Of Licensed University of California, San Diego (UCSD) Cancer Immunotherapy To Scientific Advisory Board

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, an immunotherapy company developing the ValloVax anti-angiogenic lung cancer vaccine, announced today the addition Dr. Davorka Messmer to its Scientific Advisory Board (SAB).Dr. Messmer will accelerate the clinical development of the companys cancer vaccine platform, which trains the immune system to selectively destroy the tumor-associated…

TrovaGene, Inc. To Present At Upcoming Healthcare Conferences

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ –Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference…

Batu Biologics Recruits Inventor Of Licensed University of California, San Diego (UCSD) Cancer Immunotherapy To Scientific Advisory Board

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, an immunotherapy company developing the ValloVax anti-angiogenic lung cancer vaccine, announced today the addition Dr. Davorka Messmer to its Scientific Advisory Board (SAB).Dr. Messmer will accelerate the clinical development of the companys cancer vaccine platform, which trains the immune system to selectively destroy the tumor-associated…

Ligand Pharmaceuticals Inc. Partner GlaxoSmithKline Announces EU Regulatory Submission For Severe Aplastic Anemia Indication For Revolade??? (Eltrombopag)

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade (eltrombopag), seeking an additional indication for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient…

Neurocrine Biosciences, Inc. To Present At The Jefferies and Co. 2014 Global Healthcare Conference

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in

Aegis Therapeutics, LLC Awarded Patent For Intranasal Administration Of Active Agents To The Central Nervous System

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – November 12, 2014) – Highlighted Links http://aegisthera.com Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,883,728…

Neurocrine Biosciences, Inc. To Present At The Jefferies and Co. 2014 Global Healthcare Conference

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 12, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in

Vical Incorporated To Present At The Healthcare Conference

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 11, 2014 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, November 18, at 4:10 p.m. ET at the Stifel 2014 Healthcare Conference (New York, November 18 …

Epic SciencesTo Present On Characterizing PD-L1 In Circulating Tumor Cells Of Non-Small Cell Lung Cancer Patients At The 26th EORTC-NCI-AACR Symposium

November 12, 2014 – 5:00 am | Edit Post

SAN DIEGO and BARCELONA, Spain November 12, 2014 Epic Sciences will present an analysis of PD-L1 protein expression on circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients. The poster presentation will take place November 19 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Because tumor biopsy material is often limited in…